ClinicalTrials.gg
Status unknownNCT03313362Updated Dec 20, 2019

Detecting PNES With Single-channel sEMG

An interventional study of SPEAC System and video EEG in Epilepsy, Motor Partial and Psychogenic Seizures, sponsored by Brain Sentinel. Status unknown at 3 sites in United States. Open to participants aged 22 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-12-20.

Sponsored by Brain Sentinel · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
22 Years to 99 Years
Sex
All
01

Study summary

This is a prospective, comparative, multicenter study of subjects being admitted for standard of care therapy in Epilepsy Monitoring Units in the Veteran's Affair (VA) Medical Centers.

02

Conditions studied

  • Epilepsy, Motor Partial
  • Psychogenic Seizures
03

In context

Psychogenic Nonepileptic Seizures

24 studies on the registry are indexed under Psychogenic Nonepileptic Seizures; 5 are open to participants now.

This study's enrollment of 71 is above the median of 41 across 20 interventional studies indexed under Psychogenic Nonepileptic Seizures.

Browse Psychogenic Nonepileptic Seizures studies →

Lead sponsor

Brain Sentinel is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has a history of suspected epileptic seizures with upper extremity motor involvement, or PNES with upper extremity motor involvement.
  2. Is being admitted to a hospital for routine vEEG monitoring related to seizures.
  3. Male or Female between the ages 22 to 99.
  4. If female and of , has a negative pregnancy test and must not be nursing.
  5. Can understand and sign written , or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments.
  6. Subject and/or Primary Caregiver must be competent to follow all study procedures.
  7. Subject/LAR consents to the use of vEEG files, including video/audio recordings, for purposes of this research study.

Exclusion criteria

Exclusion Criteria:

  • Intracranial EEG electrodes are being used.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Subjects admitted to Epilepsy Monitoring Units in the VAMC

    Subjects being monitored by standard of care, video EEG, in the Epilepsy Monitoring Units in the VAMC will all be placed on a Seizure Monitoring and Alerting System (SPEAC System).

    Device: SPEAC System · Device: video EEG

Interventions

  • DeviceSPEAC System

    Seizure Monitoring and Alerting System

    Also known as: Brain Sentinel Seizure Monitoring and Alerting System

  • Devicevideo EEG

    The Video EEG Monitoring Test (VEEG) is a high specialized form of an EEG test in where the patient is continuosly monitored by using a video recorder. This allows doctors to observe brainwaves activity during the time a seizure or spell is occurring.

06

What researchers measure

Primary outcomes

  1. Test an independent group of epileptologist's ability to classify motor events between epileptic or non-epileptic using sEMG and audio.

    To test the null hypothesis that three independent epileptologists categorize, by majority vote, epileptic seizures and psychogenic non-epileptic seizures (identified utilizing vEEG review) correctly in no more than 70% of cases using sEMG and audio. We aim to test the null hypothesis that the epileptologists categorize epileptic seizures and psychogenic non-epileptic seizures correctly in no more than 70% of cases. The observed rate of correct classification will be compared to the rate of 70% under the null hypothesis using a two-sided binomial exact test.

    Time frame: 1 year

Secondary outcomes

  1. To test the Brain Sentinel® Seizure Monitoring and Alerting System's ability to classify motor events as epileptic or non-epileptic.

    Test the null hypothesis that the Brain Sentinel® Seizure Monitoring and Alerting System categorizes epileptic seizures and psychogenic non-epileptic seizures (identified utilizing vEEG review) correctly in no more than 70% of cases. We aim to test the null hypothesis that the Brain Sentinel® Seizure Monitoring and Alerting System's software categorizes epileptic seizures and psychogenic Nonepileptic seizures correctly in no more than 70% of cases. The observed rate of correct classification will be compared to the rate of 70% under the null hypothesis using a two-sided binomial exact test.

    Time frame: 1 Year

07

Study locations

3 sites
  • Durham VAMC
    Durham, North Carolina 27705, United States
  • Michael E DeBakey VA Medical Center
    Houston, Texas 77030, United States
  • Hunter Holmes McGuire VA Medical Center
    Richmond, Virginia 23249, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Jun 2019, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2017
First posted
Oct 18, 2017
StartActual
Nov 3, 2017
Primary completionActual
Jun 21, 2019
CompletionEst.
Feb 2020
Last update
Dec 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03313362
Lead sponsor
Brain Sentinel
Responsible party
Sponsor
First posted
Oct 18, 2017
Start date
Nov 3, 2017
Primary completion
Jun 21, 2019
Completion
Feb 2020 (estimated)
Last update
Dec 20, 2019

Study contacts

Aatif Husain, MD
principal investigator · Epilepsy Center of Excellence (ECoE) at the Durham VA Medical Center in Durham, North Carolina
Alan Towne, MD
principal investigator · Epilepsy Center of Excellence (ECoE) at Hunter Holmes McGuire VA Medical Center in Richmond, Virginia
David Chen, MD
principal investigator · Epilepsy Center of Excellence (ECoE) at the Michael E. DeBakey VA Medical Center in Houston, Texas

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion